- Stocks
- Healthcare
- NASDAQ: SAGE

Price (delayed)

$42.72

Market cap

$2.55B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.98

Enterprise value

$2.4B

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing

The company's debt fell by 34% YoY and by 12% QoQ

The revenue has increased by 22% YoY and by 19% from the previous quarter

SAGE's quick ratio is down by 37% YoY and by 9% QoQ

SAGE's equity is down by 28% YoY and by 9% from the previous quarter

What are the main financial stats of SAGE

Market
Valuations
Earnings

Shares outstanding

59.72M

Market cap

$2.55B

Enterprise value

$2.4B

Price to earnings (P/E)

N/A

Price to book (P/B)

2.03

Price to sales (P/S)

329.63

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

312.17

Revenue

$7.69M

EBIT

-$532.78M

EBITDA

-$531.66M

Free cash flow

-$460.97M

Per share
Balance sheet
Liquidity

EPS

-$8.98

Free cash flow per share

-$7.77

Book value per share

$21.05

Revenue per share

$0.13

TBVPS

$22.87

Total assets

$1.36B

Total liabilities

$103.85M

Debt

$12.13M

Equity

$1.25B

Working capital

$1.24B

Debt to equity

0.01

Current ratio

13.47

Quick ratio

12.97

Net debt/EBITDA

0.29

Margins
Efficiency
Dividend

EBITDA margin

-6,917.3%

Gross margin

89.4%

Net margin

-6,931.9%

Operating margin

-7,116.7%

Return on assets

-34.7%

Return on equity

-37%

Return on invested capital

-41.9%

Return on capital employed

-42.4%

Return on sales

-6,931.9%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Sage Therapeutics stock price performed over time

Intraday

-1.32%

1 week

-1.39%

1 month

1.26%

1 year

22.94%

YTD

12.01%

QTD

12.01%

How have Sage Therapeutics's revenue and profit performed over time

Revenue

$7.69M

Gross profit

$6.87M

Operating income

-$546.99M

Net income

-$532.78M

Gross margin

89.4%

Net margin

-6,931.9%

The revenue has increased by 22% YoY and by 19% from the previous quarter

The company's gross profit rose by 20% QoQ and by 19% YoY

Sage Therapeutics's operating income has decreased by 19% YoY and by 5% from the previous quarter

The net income has declined by 16% year-on-year and by 4.4% since the previous quarter

What is Sage Therapeutics's growth rate over time

What is Sage Therapeutics stock price valuation

P/E

N/A

P/B

2.03

P/S

329.63

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

312.17

Sage Therapeutics's EPS has decreased by 15% YoY and by 4.2% from the previous quarter

The P/B is 44% less than the 5-year quarterly average of 3.7 but 37% more than the last 4 quarters average of 1.5

SAGE's equity is down by 28% YoY and by 9% from the previous quarter

SAGE's P/S is 40% below its 5-year quarterly average of 558.0 but 4.8% above its last 4 quarters average of 318.7

The revenue has increased by 22% YoY and by 19% from the previous quarter

How efficient is Sage Therapeutics business performance

Sage Therapeutics's ROE has plunged by 52% YoY and by 13% from the previous quarter

SAGE's ROA is down by 49% year-on-year and by 13% since the previous quarter

The ROIC has contracted by 26% YoY and by 12% from the previous quarter

Sage Therapeutics's ROS has increased by 12% from the previous quarter and by 4.5% YoY

What is SAGE's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for SAGE.

How did Sage Therapeutics financials performed over time

SAGE's quick ratio is down by 37% YoY and by 9% QoQ

The current ratio has contracted by 36% YoY and by 8% from the previous quarter

The company's debt is 99% lower than its equity

The company's debt fell by 34% YoY and by 12% QoQ

SAGE's equity is down by 28% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.